[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Aslanoğlu et al., 2024 - Google Patents

Correlation Between PSA Density and Multiparametric Prostate MRI in the Diagnosis of Prostate Cancer

Aslanoğlu et al., 2024

View HTML
Document ID
10915410938455010800
Author
Aslanoğlu A
Saygın H
Öztürk A
Ergin
Asdemir A
Velibeyoğlu A
Korgalı E
Publication year
Publication venue
Bull Urooncol

External Links

Snippet

Objective: In the diagnosis of prostate cancer, only digital rectal examination and prostate- specific antigen (PSA) testing cause unnecessary prostate biopsies, excessive cost, and treatment burden. Therefore, PSA density (PSAD) and multiparametric magnetic resonance …
Continue reading at uroonkolojibulteni.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/573—Immunoassay; Biospecific binding assay for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Similar Documents

Publication Publication Date Title
Brawer et al. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma
Terris Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: preliminary report
Constantinou et al. PSA testing: an evolving relationship with prostate cancer screening
Ross et al. Clarifying the PSA grey zone: The management of patients with a borderline PSA
Tidd-Johnson et al. Prostate cancer screening: Continued controversies and novel biomarker advancements
Kobayashi et al. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population
Gómez‐Gómez et al. Plasma ghrelin O‐acyltransferase (GOAT) enzyme levels: A novel non‐invasive diagnosis tool for patients with significant prostate cancer
Rico et al. Value of prostate-specific antigen density in negative or equivocal lesions on multiparametric magnetic resonance imaging
Ma et al. Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI
Kido et al. Multidimensional analysis of clinicopathological characteristics of false-negative clinically significant prostate cancers on multiparametric MRI of the prostate in Japanese men
Masters et al. Free/total serum prostate‐specific antigen ratio: how helpful is it in detecting prostate cancer?
Noguchi et al. Necessity of repeat biopsies in men for suspected prostate cancer
Wieczorek et al. Inosine monophosphate dehydrogenase 2 as a marker of aggressive and advanced prostate cancer
Amayo et al. Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of the prostate
Cooner Definition of the ideal tumor marker
Shan et al. The influence of prostate volume on clinical parameters in prostate cancer screening
Aslanoğlu et al. Correlation Between PSA Density and Multiparametric Prostate MRI in the Diagnosis of Prostate Cancer
Sakai et al. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men
Kato et al. Clinical significance of urinary white blood cell count and serum C‐reactive protein level for detection of non‐palpable prostate cancer
Bıçaklıoğlu et al. The Predictive Ability of Prostate-Specific Antigen (PSA) Density and Free/Total PSA Ratio in Diagnosing Clinically Significant Prostate Cancer (PCa) in Patients with Histologically Confirmed PCa with a PSA Level of 2.5-10 Ng/ML
Kobayashi et al. Prostate‐specific antigen (PSA) complexed to α1‐antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0–4.0 ng/mL
Arıkan et al. Prognostic Role of Tumor Percentage in Multiparametric MRI for Upgrade Prediction Before Radical Prostatectomy
Çelikkaleli et al. Combining Multiparametric MRI and PSA Density for Improved Diagnostic Accuracy in Prostate Cancer
Chiu et al. Prostate biopsy strategy integrating prostate health index and multiparametric magnetic resonance imaging optimizes the predictive value of clinically significant prostate cancer in prostate imaging reporting and data system gray-zone imaging
Keskin et al. Predictive Value of PSA Density in Pathological Discordance Terms in Patients who Undergo Robotic Surgery for Low-risk Prostate Cancer: An Analytic Cross-sectional Study of a Tertiary Reference Center